Several changes to the membership of the Board of Directors of Ocular Therapeutix, Inc. are expected to occur in connection with the Company’s 2019 annual meeting of stockholders scheduled to be held on June 11, 2019. On April 17, 2019, W. James O’Shea notified the Company of his resignation as a member of the Board, effective and contingent upon the conclusion of the 2019 Annual Meeting. Mr. O’Shea is a class I director whose term was otherwise scheduled to expire at the Company’s annual meeting of stockholders to be held in 2021. Mr. O’Shea’s resignation from the Board was not the result of any disagreement with the Company. In addition, the Board has nominated Seung Suh (Stanley) Hong for election as a class II director to assume the Board seat currently occupied by Jaswinder Chadha. Mr. Chadha’s term as a director is scheduled to expire at the 2019 Annual Meeting. The decision to nominate Dr. Hong was not the result of any disagreement between Mr. Chadha and the Company. Dr. Hong has served as a consultant to a number of biopharmaceutical companies since March 2019. From April 2002 to January 2019, he served in various capacities at Celltrion Inc., including as President of Celltrion Healthcare Japan and Senior Advisor from January 2016 to January 2019; as President and Chief Executive Officer of Celltrion Healthcare Co. Ltd. from November 2014 to December 2015; and as President of Research and Development from April 2002 to November 2014. Following the 2019 Annual Meeting, it is expected that the Board will consist of eight members with no vacancies.